Loading
A phase 2 trial of Anvumetostat in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) is a phase 2 interventional study registered as NCT06593522 by Amgen, with 61 participants enrolled, started 2024-12-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: anvumetostat.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Anvumetostat, Amgen and the tag pipeline.
Shares Amgen, Non-small-cell lung cancer and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Amgen and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/